2014年9月29日meta每周记录第四周

1、： 。 再交流： 。 再交流第四 Harmon W, Meyers K, Ingelfinger J, McDonald R, McoshM,HoM,SpaneasL,PalmerJA,HawkM,GeehanC,Tinc Hancock WW, Sayegh MH.JAmSocNephrol.2006Jun;17(6):1735-45.Epub2006May EttengerR,F,GrimmP,WebbN,LoiratC,MahanJD,MentserM,NiaudetP,OffnerG,Vandamme-LombaertsHexhamJM;EverolimusPediatricStudy

2、 C,BenzK,AmannK,NskenKD,DittrichK,RascherW,SauersteinK,StuppyA,KlareB,DtschNephrolDialTransplant.2006Oct;21(10):2930-7.Epub2006Jul to monotherapy enance in pediatric renal transplant recipients: a single PMID:21155956PubMed-indexedforTable1.TheCharacteristicsofIndividual第一篇（William Harmon et al, 200

3、6：34 人入组这个预试验，203年以上，1个未能做成肾移植，8个因为急性排斥终止试验，4第二篇（Kar n Cransberg et al, 2007：1998 initial immunosuppressive triple therapy consistingTable1.TheCharacteristicsofIndividual第一篇（William Harmon et al, 2006：34 人入组这个预试验，203年以上，1个未能做成肾移植，8个因为急性排斥终止试验，4第二篇（Kar n Cransberg et al, 2007：1998 initial immunosuppr

4、essive triple therapy consisting of corticosteroids, CsA, and MMF.kly dose-reduction to 7.5mg/m2 once daily at ksand 5 mg/m2 at 6 months after transplant6200-250 微克/L6 150-200 微克/L，3 莱，环孢素直到移植肾有功能后才用。received triple 量直（Thethirddrugwas discontinued control groupleWilliam Harmon et al, 2006PilotJAmSoc

5、 0Kar n Cransberg et al, CsAandMMF或 2001 MMFbasiliximabFlow chart thestudy 为准Benfield MR et al, 2005本文比较的是OKT3 meta？素（Sandimmune or Neoral）+强的松+AZA/MMF分割线-12 DataExtraction (1)thenameofauthorandthepublication(2)thestudydesignandle(3)thetthe分割线-12 DataExtraction (1)thenameofauthorandthepublication(2)

6、thestudydesignandle(3)thetthepatientsthesourceofthedata including patient survival, graft survival, acute rejection, renal function, urinary tract (CMV)t-transplantdiabetesmellitus,emia,Calcineurin Inhibitor Avoidance and Withdrawal for Kidney Transplan ysis of Randomized Controlled Trials 这篇的搜索策略。i

7、on: A Systematic Review and calcineurin-inhibitor sparing regimens OR calcineurin inhibitor free OR calcineurin inhibitor avoidance calcineurininhibitorwithdrawalORalcineurin (pediatricsMeSH Terms OR pediatricsAll Fields OR pediatricAll Fields) AND (kidney Terms OR (kidneyAll Fields AND ionAll Field

8、s) OR kidney ionAll Fields OR Fields AND ionAll Fields) OR renal ionAll Fields) OR (pediatricsMeSH Terms pediatricsAllFieldsORpediatricAllFields)AND(kidneyionMeSHTermsOR(kidneyAllFields FieldsANDregimensAllFields)OR(calcineurinMeSHTermsORcalcineurinAllFields)ANDinhibitorAllFieldsfreeAll Fields) OR (

9、calcineurinMeSH Terms OR calcineurinAll Fields) AND inhibitorAll Fields AND avoidanceAll Fields)OR(calcineurinMeSHTermsORcalcineurinAllFields)ANDinhibitorAllFieldsANDwithdrawalAllFields)OR (calcineurinMeSHTermsORcalcineurinAllFields)ANDinhibitorAllFields)ANDRandomizedControlledTrialptypTitle: Random

10、ized trial of tacrolimus versus cyclospor in renal transplanion这一篇根本不能从题目当Author:Trompeter,R.;Filler,G.;Webb,N.J.(.) Source: Pediatr Nephrol, 2002, 17(3): 141-149:Thisstudywasundertakentocomparetheefficacyandsafetyoftacrolimus(Tac) withtheofcyclosporin(CyA)inchildrenundergoingrenal study n open phas

11、e was conducted in 18 centers from nine European otal, 196 patients(18years)wererandomlyassigned(1:1)toreceiveeitherTac(n=103)orCyAThisstudywasundertakentocomparetheefficacyandsafetyoftacrolimus(Tac) withtheofcyclosporin(CyA)inchildrenundergoingrenal study n open phase was conducted in 18 centers fr

12、om nine European otal, 196 patients(18years)wererandomlyassigned(1:1)toreceiveeitherTac(n=103)orCyA(n=93)itantlyzathioprineandcorticosteroids.Theprimarywasincidenceandtimeacute Baselinecharacteristicswerentreatmentgroups.Tactherapyresultedinasignificantlylower wasalsosignificantlyheTacgroupcomparedw

13、iththeCyAgroup(7.8%vs.25.8%,P=0.001).Thevs. 96.6%), while 10 grafts were he Tac group compared with 17graft he CyA group ( P=0.06). At 1 meanglomerularfiltrationrate(Schwartzestimate)wassignificantlyheTacgroup(62+/-20ml/minper1.73nhe CyAgroup (56+/-21ml/min per1.73m(2), n=74, P=0.03). The most frequent adverse events during 6monthswere (29.1%vs.33.3%).isticallysignificant(P30 days) insulin use was 3.0% (Tac) and 2.2% t-transplant lymphopro